Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This study aims to test if patients achieving a tumor response with the combination of
axitinib plus avelumab, can discontinued the axitinib in order to delay the resistance to the
anti VEGFR-TKI and decrease the related toxicity of the combination therapy.